Ana Figueiredo

Ana Figueiredo

Auto-generated profile, based on publicly available information

Ana Figueiredo

Gulbenkian Institute of Molecular Medicine

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Pharmacological Research
Verified
Journal Article
Closed access
AFAna Figueiredo
Ana Figueiredo
ELErmelindo Carreira Leal
Ermelindo Carreira Leal
ECEugénia Carvalho
Eugénia Carvalho

12 June 2025 in Science
Verified
Journal Article
Closed access
AFAna Figueiredo
Ana Figueiredo
SRSonia Trikha Rastogi
Sonia Trikha Rastogi
SRSusana Ramos
Susana Ramos
Fatima NogueiraFatima Nogueira
Fatima Nogueira
KVKatherine De Villiers
Katherine De Villiers
MSMiguel P. Soares
Miguel P. Soares
Jaundice is a common presentation of Plasmodium falciparum malaria, which arises from the accumulation of circulating bilirubin. It is not understood whether it represents an adaptive or maladaptive response to Plasmodium spp. infection. We found that asymptomatic P. falciparum infection in humans was associated with a higher ratio of unconjugated over conjugated bilirubin and parasite burden compared with symptomatic malaria. Genetic suppression of bilirubin synthesis by biliverdin reductase A (BVRA) increased parasite virulence and malaria mortality in mice. Accumulation of unconjugated bilirubin in plasma, through genetic inhibition of hepatic conjugation by UDP glucuronosyltransferase family 1 member A1 (UGT1A1), was protective against malaria in mice. Unconjugated bilirubin inhibited P. falciparum proliferation in red blood cells by a mechanism that suppressed mitochondrial pyrimidine synthesis. Moreover, unconjugated bilirubin inhibited hemozoin crystallization and compromised the parasite’s food vacuole. Hence, jaundice appears to represent a metabolic response to Plasmodium spp. infection that limits malaria severity.

1 June 2020 in Diabetes
Verified
Journal Article
Closed access
ELErmelindo Carreira Leal
Ermelindo Carreira Leal
AFAna Figueiredo
Ana Figueiredo
ECEugenia Carvalho
Eugenia Carvalho
Diabetic neuropathy plays an important role in the development of chronic wounds. Endothelial progenitor cells (EPCs) are known important regulators of wound angiogenesis. However, the role of neuropeptides in EPC function, and particularly Neurotensin (NT), is unknown in diabetic wound healing. EPCs isolated from normal mice were cultured in high glucose (25 mM) or normoglicemia (5.5 mM) and treated with NT (25-400 nM) for 3 days. Moreover, EPCs isolated from streptozotocin (STZ)-induced diabetic mice were treated with NT (100 nM) for 3 days. Subsequently, EPC viability, cell adhesion and reactive oxygen species (ROS) levels were evaluated. To the in vivo wound healing model, 6 mm wounds were created in the dorsum of diabetic mice and wound progression was followed up to day 10. The wound edges were injected with ex-vivo diabetic bone marrow derived EPCs treated in culture with NT (100 nM) for 3 days, or EPCs without NT treatment, or vehicle. Angiogenesis was evaluated by immunohistochemistry. The viability of EPCs cultured under high glucose or EPCs from diabetic mice was improved by NT treatment. Also, EPCs from diabetic mice showed decreased adhesion (58% of control, p<0.05) and increased ROS levels (148% of control, p<0.05) when compared to control EPCs, and these effects were reversed by NT treatment. In addition, NT-treated EPCs, from diabetic mice, improved wound closure (day 10, 4% of original wound size) when compared with non-treated EPCs or vehicle (day 10, 32% and 35% of original wound size, respectively, p<0.05). Furthermore, NT-treated EPCs, from diabetic mice, increased neovascularization at the wound site (153% of vehicle, p<0.05) when compared with non-treated EPCs (115% of vehicle) or vehicle. These results show that neurotensin is able to improve the function of EPCs from diabetic animals, which are able to improve wound healing by promoting angiogenesis. The restoration of EPC function by neurotensin could improve their therapeutic effect for the treatment of chronic diabetic wounds. Disclosure E.C. Leal: None. A. Figueiredo: None. E. Carvalho: None. Funding Portuguese Foundation for Science and Technology; European Foundation for the Study of Diabetes; Portuguese Society of Diabetology

22 December 2025 in bioRxiv
Verified
Preprint
Open access
MMMiguel Mesquita
Miguel Mesquita
AFAna Figueiredo
Ana Figueiredo
SRSonia Trikha Rastogi
Sonia Trikha Rastogi
SRSusana Ramos
Susana Ramos
SPSara Pagnotta
Sara Pagnotta
MSMiguel P. Soares
Miguel P. Soares
Jaundice, a condition characterized by elevated levels of circulating bilirubin, is an adaptive response to malaria sustained through bilirubin production by biliverdin reductase A (BVRA). Beyond its enzymatic activity, BVRA acts as a protein kinase and as a transcription factor. To disentangle the contribution of BVRA catalytic activity over its non-canonical functions we generated Blvra G17A and Blvra E97A mice harboring G17A and E97A missense mutations in the BVRA NAD(P)H-binding domain and reductase motif, respectively. Both Blvra G17A and Blvra E97A mice presented a reduction in enzymatic activity and succumbed to malaria, otherwise non-lethal to wild-type ( Blvra WT ) mice. Quantification of circulating unconjugated bilirubin revealed a dose response effect whereby the mutant strains failed to reach a threshold of circulating bilirubin required to support its protective effect. These findings establish the antimalarial effect of the enzymatic activity of BVRA and define a concentration threshold of bilirubin required for malaria protection, informing therapeutic development and biomarker-guided malaria treatment strategies. Highlights: - Establishment of catalytic deficient BVRA mouse mutants; - Anti-malarial effect of BVRA relies on its catalytic activity; - A minimal bilirubin threshold for parasite control; - A minimal bilirubin threshold for malaria resolution;

26 June 2026 in bioRxiv
Verified
Preprint
Open access
MMMiguel Mesquita
Miguel Mesquita
MPMaria Pires
Maria Pires
SVSara Violante
Sara Violante
JKJamil Kitoko
Jamil Kitoko
MCMartim Costa
Martim Costa
MSMiguel Soares
Miguel Soares
Iron deficiency anemia affects one-third of the global human population. Paradoxically, the daily iron required to fuel the production red blood cell (RBC) and prevent anemia is provided through its recycling from senescent RBC. This is achieved by splenic red pulp macrophages (RPM) that extract iron from the heme groups of hemoglobin (Hb). How these professional erythrophagocytic macrophages prevent intracellular iron flux from inducing cell death via ferroptosis is unknown. Here we show that SPI-C, the master transcriptional regulator of the erythrophagocytic lineage, orchestrates two redundant anti-ferroptosis pathways. One supports glutathione synthesis, via NF-E2-related factor 2 (NRF2), and the other relies on bilirubin production by biliverdin reductase A (BVRA). Genetic ablation of both pathways, but not either alone, sensitizes erythrophagocytic macrophages to ferroptosis, depletes RPM and increases the severity of iron deficiency anemia in mice. These findings reveal a central physiologic role of ferroptosis in the control of macrophage function, iron homeostasis and iron-deficiency anemia.

12 August 2026 in Trends in Parasitology
Verified
Journal Article
Closed access
MSMiguel P. Soares
Miguel P. Soares
MMMiguel Mesquita
Miguel Mesquita
AFAna Figueiredo
Ana Figueiredo